D-Keine Deals and Financings Hangzhou Sciwind Biosciences out-licensed South Korean rights for ecnoglutide injection (XW003), a novel long-acting GLP-1 analog aimed at type 2 diabetes, obesity and MASH, to HK inno.N Corporation (KOSDAQ: 195940). HK inno.N is a South Korean commercial stage pharmaceutical company. Sciwind will receive an unspecified upfront payment and additional milestones of…
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Businesses have rushed to tap lenders in the $10tn US corporate bond market this week, taking advantage of feverish investor demand and low borrowing premiums to issue swaths of new debt. High-yield or junk-rated companies…
We Are M&G (OTCPK:MGPFY)(OTCPK:MGPUF) is an asset management and increasingly an insurance play as it re-enters its bulk annuity business. We see some offset of run-off there in addition to the higher return on the excess assets. There should be continued lift in that business as the new annuity buy ins become recognised on a…
piranka/E+ via Getty Images Investment Thesis Intellicheck, Inc. (NASDAQ:IDN) faced a series of challenges, including sales execution issues and a notable concentration of customers within the retail sector, which proved vulnerable during periods of economic downturn. This led to a dip in revenue growth, and since then, the company has struggled to re-accelerate growth to…
jewhyte I published my ‘Strong Buy’ thesis for Microsoft (NASDAQ:MSFT) in my initiation report, published in July 2023. Since then, the stock price has surged by about 17%. I highlighted Microsoft’s capability to integrate AI-powered features into all their software and platforms. They released their Q3 FY24 earnings on April 25th with 17% of constant…
PeopleImages Deals and Financings GSK acquired ex-Greater China rights to a second ADC from Jiangsu’s Hansoh Pharma in a $1.7 billion agreement (see story). GSK’s latest acquisition, HS-20093, is a B7-H3 targeted antibody-drug conjugate (ADC) with a topoisomerase inhibitor (TOPOi) payload that is in China Phase I/II trials for solid tumor cancers. Hansoh will receive…
deliormanli As China’s pharmaceutical sector battles through tough times, some biotechs are still managing to push ahead with novel drugs and make money along the way. HBM Holdings Ltd. (OTCPK:HBMHF) (2142.HK), for one, has found strength in numbers, striking drug development agreements with a host of prominent partners. On Friday came news of another licensing-out…
porcorex Despite expectations of some major post-Thanksgiving launches, just two small Asian issuers listed in the US this past week. Hong Kong-based financial services firm Garden Stage (GSIW) offered more shares and priced at the low end to raise $10 million at a $64 million market cap. Through its subsidiaries, the company provides placement and…
DKosig Investment Thesis InterDigital, Inc. (NASDAQ:IDCC) delivered Q3 2023 results which were mixed. On the one hand, there’s enough in this set of results to put a solid BUY rating on this stock. Not only was the sale of two license agreements very welcome on the top line, but it also allowed IDCC’s free cash…
The ongoing lawsuit has a complaint against Mercedes F1 that echoes the accusations, asserting that the team prominently featured FTX’s logo on its cars, merchandise, and marketing materials. A group of FTX users has filed twin class-action lawsuits in a Florida district court, accusing the Mercedes-AMG Petronas F1 Team and Major League Baseball (MLB) of…
Zerbor/iStock via Getty Images By James T. Tierney, Jr. Recent labor agreements in the auto and airline industries spotlight the profitability conundrum facing US companies – and equity investors. Pricing power and cost containment are essential ingredients for companies looking to expand profit margins. We’ve seen this clearly in 2023, when some of the best-performing…
Drew Angerer Thesis In this analysis of Palantir Technologies, Inc. (NYSE:PLTR), I will elucidate the compelling reasons why Palantir remains a “strong buy” even after experiencing a substantial rally of over 169%. According to my calculations, should analysts’ estimates materialize, the stock has the potential to ascend to $49.6, reflecting a significant upside. In light…
VioletaStoimenova In November of last year, I believed that AMETEK, Inc. (NYSE:AME) was putting some money to work again, announcing two bolt-on deals after 2022 has been quite strong so far. Liking the performance of the business and its strategy, I was upbeat on the business but found the valuation a bit too demanding to…
kentoh/iStock via Getty Images Deals and Financings Suzhou MediLink Therapeutics out-licensed global rights (ex-China) for its antibody-drug conjugate candidate against Human Epidermal Growth Factor Receptor 3 (HER3) to BioNTech (BNTX) in a $1.1 billion agreement (see story). BioNTech will pay $70 million upfront to MediLink and be responsible for more than $1 billion in milestone…
Ethan Miller/Getty Images News Investment Thesis Qualcomm (NASDAQ:QCOM) is an American semiconductor firm specializing in mobile and IoT technologies. QCOM saw a pullback in 3Q23 amid weaker-than-expected results and headwinds. Despite this, it remains a market leader, paying a 2.8% dividend yield. The investment case has been reinforced with the renewal of the Apple (AAPL)…
A large chunk of OKX’s $25-$50 million annual advertising budget goes towards its sports deals. Crypto exchange OKX wants its deals with Formula 1 team McLaren and UEFA Champions League-winning team Manchester City to last a decade. The company reportedly spends $25-$50 million per year in its sponsorship deals with the two sports teams. OKX’s…
According to the filing, the payments in question are characterized as “certain prepayments related to various advertising and sponsorship agreements, security deposits, retainers, and other miscellaneous deposits and prepayments.” In a recent court filing, the current management of the defunct FTX Derivatives Exchange has shed light on the intricate web of marketing and sponsorship deals…